The role of glucose transporter 1 (GLUT1) in the diagnosis and therapy of tumors;Rola transportera glukozy 1 (GLUT1) w diagnostyce i terapii nowotworów

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 66, Issue , 2012, Pages 165-174

  Jóźwiak, Paweł ^a   Lipińska, Anna ^a  

^a UNIVERSITY OF LODZ   (Poland)

Author keywords

Cancer; Glucose analogs; GLUT1; Glycolysis; HIF 1; MTOR; Oncogene

Indexed keywords

GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TUMOR MARKER;

CANCER GRADING; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; NEOPLASM; ONCOGENE; OXIDATIVE PHOSPHORYLATION; PATHOLOGY; PROGNOSIS; REVIEW; TRANSPORT AT THE CELLULAR LEVEL; UPREGULATION;

BIOLOGICAL TRANSPORT; GENE EXPRESSION; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MOLECULAR STRUCTURE; NEOPLASM GRADING; NEOPLASMS; ONCOGENES; OXIDATIVE PHOSPHORYLATION; PROGNOSIS; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84862508057     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Aft R. L., Zhang F. W., Gius D.: Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death. Br. J. Cancer, 2002;87:805-812
2. Airley R. E., Mobasheri A.: Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy, 2007;53:233-256
3. Appleman J. R., Lienhard G. E.: Kinetics of the purified glucose transporter. Direct measurement of the rates of interconversion of transporter conformers. Biochemistry, 1989;28:8221-8227
4. Ayala F. R., Rocha R. M., Carvalho K. C., Carvalho A. L., da Cunha I. W., Lourenço S. V., Soares F. A.: Glut1 and Glut3 as potential prognostic markers for oral squamous cell carcinoma. Molecules, 2010;15:2374-2387
5. Bloch R.: Inhibition of glucose transport In the human erythrocyte by cytochalasin B. Biochemistry, 1973;12:4799-4801
6. Brockmann K.: The expanding phenotype of GLUT1-deficiency syndrome. Brain Dev., 2009;31:545-552
7. Buse M. G., Robinson K. A., Marshall B. A., Hresko R. C., Mueckler M. M.: Enhanced O-GlcNAc protein modifcation is associated with insulin resistance in GLUT1-overexpressing muscles. Am. J. Physiol. Endocrinol. Metab., 2002;283:E241-E250
8. Calvo M. B., Figueroa A., Pulido E. G., Campelo R. G., Aparicio L. A.: Potential role of sugar transporters in cancer and their relationship with anticancer therapy. Int. J. Endocrinol., 2010;2010:205357
9. Castro A. F., Rebhun J. F., Clark G. J., Quilliam L. A.: Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin-and farnesylation-dependent manner. J. Biol. Chem., 2003;278:32493-32496
10. Chan J. Y., Kong S. K., Choy Y. M., Lee C. Y., Fung K. P.: Inhibition of glucose transporter gene expression by antisense nucleic acids in HL-60 leukemia cells. Life Sci., 1999;65:63-70
11. Choo A. Y., Yoon S. O., Kim S. G., Roux P. P., Blenis J.: Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc. Natl. Acad. Sci. USA, 2008;105:17414-17419
12. Chung F. Y., Huang M. Y., Yeh C. S., Chang H. J., Cheng T. L., Yen L. C., Wang J. Y., Lin S. R.: GLUT1 gene is a potential hypoxic marker in colorectal cancer patients. BMC Cancer, 2009;9:241
13. Cifuentes M., García M. A., Arrabal P. M., Martínez F., Yañez M. J., Jara N., Weil B., Domínguez D., Medina R. A., Nualart F.: Insulin regulates GLUT1-mediated glucose transport In MG-63 human osteosarcoma cells. J. Cell. Physiol., 2011;226:1425-1432
14. Cloherty E. K., Levine K. B., Carruthers A.: The red blood cell glucose transporter presents multiple, nucleotide-sensitive sugar exit sites., Biochemistry, 2001;40:15549-15561
15. Cope D. L., Holman G. D., Baldwin S. A., Wolstenholme A. J.: Domain assembly of the GLUT1 glucose transporter. Biochem J., 1994;300:291-294
16. Díaz M., Vraskou Y., Gutiérrez J., Planas J. V.: Expression of rainbow trout glucose transporters GLUT1 and GLUT4 during in vitro muscle cell differentiation and regulation by insulin and IGF-I. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2009;296:R794-R800
17. Downward J.: Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer, 2003;3:11-22
18. Ferreira L. M. R.: Cancer metabolism: the Warburg effect today. Exp. Mol. Pathol., 2010;89:372-380
19. Frolova A., Flessner L., Chi M., Kim S. T., Foyouzi-Yousefi N., Moley K. H.: Facilitative glucose transporter type 1 is differentially regulated by progesterone and estrogen in murine and human endometrial stromal cells. Endocrinology, 2009;150:1512-1520
20. Furuta E., Okuda H., Kobayashi A., Watabe K.: Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim. Biophys. Acta, 2010;1805:141-152
21. Ganapathy V., Thangaraju M., Prasad P. D.: Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol. Ther., 2009;121:29-40
22. Grolleau A., Bowman J., Pradet-Balade B., Puravs E., Hanash S., Garcia-Sanz J. A., Beretta L.: Global and specific translational control by rapamycin in T cells uncovered by microarrays and proteomics. J. Biol. Chem., 2002;277:22175-22184
23. Hamilton B. J., Nichols R. C., Tsukamoto H., Boado R. J., Pardridge W. M., Rigby W. F.: hnRNP A2 and hnRNP L bind the 3'UTR of glucose transporter 1 mRNA and exist as a complex in vivo. Biochem. Biophys. Res. Commun., 1999;261:646-651
24. Hayashi M., Sakata M., Takeda T., Yamamoto T., Okamoto Y., Sawada K., Kimura A., Minekawa R., Tahara M., Tasaka K., Murata Y.: Induction of glucose transporter 1 expression through hypoxia-inducible factor 1α under hypoxic conditions in trophoblast-derived cells. J. Endocrinol., 2004;183:145-154
25. Hebert C., Norris K., Parashar P., Ord R. A., Nikitakis N. G., Sauk J. J.: Hypoxia-inducible factor-1α polymorphisms and TSC1/2 mutations are complementary in head and neck cancers. Mol. Cancer, 2006;5:3
26. Hruz P. W., Mueckler M. M.: Structural analysis of the GLUT1 facilitative glucose transporter (review). Mol. Membr. Biol., 2001;18:183-193
27. Ikenoue T., Inoki K., Yang Q., Zhou X., Guan K. L.: Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J., 2008;27:1919-1931
28. Jefferies H. B., Reinhard C., Kozma S. C., Thomas G.: Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family. Proc. Natl. Acad. Sci. USA, 1994;91:4441-4445
29. Jeong J. W., Bae M. K., Ahn M. Y., Kim S. H., Sohn T. K., Bae M. H., Yoo M. A., Song E. J., Lee K. J., Kim K. W.: Regulation and destabilization of HIF-1α by ARD1-mediated acetylation. Cell, 2002;111:709-720
30. Jokilehto T., Jaakkola P. M.: The role of HIF prolyl hydroxylases in tumour growth. J. Cell. Mol. Med., 2010;14:758-770
31. Joost H. G., Thorens B.: The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members. Mol. Membr. Biol., 2001;18:247-256
32. Kasahara T., Maeda M., Boles E., Kasahara M.: Identification of a key residue determining substrate affinity in the human glucose transporter GLUT1. Biochim. Biophys. Acta, 2009;1788:1051-1055
33. Kawamura T., Kusakabe T., Sugino T., Watanabe K., Fukuda T., Nashimoto A., Honma K., Suzuki T.: Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer, 2001;92:634-641
34. KC S., Cárcamo J. M., Golde D. W.: Vitamin C enters mitochondria via facilitative glucose transporter 1 (Glut1) and confers mitochondrial protection against oxidative injury. FASEB J., 2005;19:1657-1667
35. Krześlak A.: Kinaza Akt: kluczowy regulator metabolizmu i progresji nowotworów. Postȩpy Hig. Med. Dośw., 2010;64:490-503
36. Krzyżowska M., Swia̧tek W., Fijałkowska B., Niemiałtowski M., Schollenberger A.: Rola kinaz MAP w odpowiedzi immunologicznej. Postȩpy Biol. Kom., 2009;36:295-308
37. Kurtoglu M., Gao N., Shang J., Maher J. C., Lehrman M. A., Wangpaichitr M., Savaraj N., Lane A. N., Lampidis T. J.: Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol. Cancer Ther., 2007;6:3049-3058
38. Land S. C., Tee A. R.: Hypoxia-inducible factor 1 a is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J. Biol. Chem., 2007;282:20534-20543
39. Levy Y., Onuchic J. N.: Water and proteins: a love-hate relationship. Proc. Natl. Acad. Sci. USA, 2004;101:3325-3326
40. Liu Q., Vera J. C., Peng H., Golde D. W.: The predicted ATP-binding domains in the hexose transporter GLUT1 critically affect transporter activity. Biochemistry, 2001;40:7874-7881
41. Maher J. C., Savaraj N., Priebe W., Liu H., Lampidis T. J.: Differential sensitivity to 2-deoxy-D-glucose between two pancreatic cell lines correlates with GLUT1 expression. Pancreas, 2005;30:e34-e39
42. Maiden M. C., Davis E. O., Baldwin S. A., Moore D. C., Henderson P. J.: Mammalian and bacterial sugar transport protein are homologous. Nature, 1987;325:641-643
43. Manning B. D., Tee A. R., Logsdon M. N., Blenis J., Cantley L. C.: Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinisitide 3-kinase/Akt pathway. Mol. Cell, 2002;10:151-162
44. Manolescu A. R., Witkowska K., Kinnaird A., Cessford T., Cheeseman C.: Facilitated hexose transporters: new perspectives on form and function. Physiology. 2007;22:234-240
45. 2 induce GLUT1 translocation in M07e cells. Biofactors, 2004;20:97-108
46. Maschek G., Savaraj N., Priebe W., Braunschweiger P., Hamilton K., Tidmarsh G. F., De Young L. R., Lampidis T. J.: 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res., 2004;64:31-34
47. Maxwell P. H., Dachs G. U., Gleadle J. M., Nicholls L. G., Harris A. L., Stratford I. J., Hankinson O., Pugh C. W., Ratcliffe P. J.: Hypoxiainducible factor-1 modulates gene expression in solid tumors and infuences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA, 1997;94:8104-8109
48. Melstrom L. G., Salabat M. R., Ding X. Z., Milam B. M., Strouch M., Pelling J. C., Bentrem D. J.: Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. Pancreas, 2008;37:426-431
49. Mitani T., Hoshikawa H., Mori T., Hosokawa T., Tsukamoto I., Yamaguchi F., Kamitori K., Tokuda M., Mori N.: Growth inhibition of head and neck carcinomas by D-allose. Head Neck, 2009;31:1049-1055
50. Moin S. M., Chandra V., Arya R., Jameel S.: The hepatitis E virus ORF3 protein stabilizes HIF-1a and enhances HIF-1 mediated transcriptional activity through p300/CBP. Cell. Microbiol., 2009;11:1409-1421
51. Mori Y., Tsukinoki K., Yasuda M., Miyazawa M., Kaneko A., Watanabe Y.: Glucose transporter type 1 expression are associated with poor prognosis in patients with salivary gland tumors. Oral Oncol., 2007;43:563-569
52. Murakami T., Nishiyama T., Shirotani T., Shinohara Y., Kan M., Ishii K., Kanai F., Nakazuru S., Ebina Y.: Identification of two enhancer elements in the gene encoding the type 1 glucose transporter from the mouse which are responsive to serum, growth factor and oncogenes. J. Biol. Chem., 1992;267:9300-9306
53. Naftalin R. J.: Alternating carrier models of asymmetric glucose transport violate the energy conservation laws. Biophys J., 2008;95:4300-4314
54. Nakajo M., Kajiya Y., Tani A., Yoneda S., Shirahama H., Higashi M., Nakajo M.: 18FDG PET for grading malignancy in thymic epithelial tumors: significant differences in 18FDG uptake and expression of glucose transporter-1 and hexokinase II between low and high-risk tumors: Preliminary study. Eur. J. Radiol., 2012;81:146-151
55. Noguchi Y., Saito A., Miyagi Y., Yamanaka S., Marat D., Doi C., Yoshikawa T., Tsuburaya A., Ito T., Satoh S.: Suppression of facilitative glucose transporter 1 mRNA can suppress tumor growth. Cancer Lett., 2000;154:175-182
56. Noto Y., Iwazaki A., Nagao J., Sumiyama Y., Redpath J. L., Stanbridge E. J., Kitagawa T.: Altered N-Glycosylation of glucose transporter-1 associated with radiation-induced tumorigenesis of human cell hybrids. Biochem. Biophys. Res. Commun., 1997;240:395-398
57. Nurzyńska D.: Hamowanie onkogenów za pomoca̧ oligonukleotydów antysensowych jako metoda terapii nowotworów. Współczesna Onkologia, 2003;7:18-23
58. Osthus R. C., Shim H., Kim S., Li Q., Reddy R., Mukherjee M., Xu Y., Wonsey D., Lee L. A., Dang C. V.: Deregulation of glucose transporter 1 and glycolytic gene expression by c-myc. J. Biol. Chem., 2000;275:21797-21800
59. Pagé E. L., Chan D. A., Giaccia A. J., Levine M., Richard D. E.: Hypoxiainducible factor-1a stabilization in nonhypoxic conditions: role of oxidation and intracellular ascorbate depletion. Mol. Biol. Cell, 2008;19:86-94
60. Pérez A., Ojeda P., Valenzuela X., Ortega M., Sánchez C., Ojeda L., Castro M., Cárcamo J. G., Rauch M. C., Concha I. I., Rivas C. I., Vera J. C., Reyes A. M.: Endofacial competitive inhibition of the glucose transporter 1 activity by gossypol. Am. J. Physiol. Cell Physiol., 2009;297:c86-c93
61. Ravazoula P., Batistatou A., Aletra C., Ladopoulos J., Kourounis G., Tzigounis B.: Immunohistochemical expression of glucose transporter Glut1 and cyclin D1 in breast carcinomas with negative lymph nodes. Eur. J. Gynaecol. Oncol., 2003;24:544-546
62. Rees W. D., Holman G. D.: Hydrogen bonding requirements for the insulin-sensitive sugar transport system of rat adipocytes. Biochim Biophys. Acta, 1981;646:251-260
63. Robichaud T., Appleyard A. N., Herbert R. B., Henderson P. J., Carruthers A.: Determinants of ligand binding affinity and cooperativity at the GLUT1 endofacial side. Biochemistry, 2011;50:3137-3148
64. Rosner M., Hengstschläger M.: Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1. Hum. Mol. Genet., 2008;17:2934-2948
65. Roux P. P., Ballif B. A., Anjum R., Gygi S. P., Blenis J.: Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc. Natl. Acad. Sci. USA, 2004;101:13489-13494
66. Samih N., Hovsepian S., Notel F., Prorok M., Zattara-Cannoni H., Mathieu S., Lombardo D., Fayet G., El-Battari A.: The impact of N-and O-glycosylation on the functions of Glut-1 transporter in human thyroid anaplastic cells. Biochim. Biophys. Acta, 2003;1621:92-101
67. Santalucía T., Christmann M., Yacoub M. H., Brand N. J.: Hypertrophic agonists induce the binding of c-Fos to an AP-1 site in cardiac myocytes: implications for the expression of GLUT1. Cardiovasc. Res., 2003;59:639-648
68. Sato M., Mueckler M.: A conserved amino acid motif (R-X-G-R-R) in the Glut1 glucose transporter is an important determinant of membrane topology. J. Biol. Chem., 1999;274:24721-24725
69. Saxena N., Lahiri S. S., Hambarde S., Tripathi R. P.: RAS: target for cancer therapy. Cancer Invest., 2008;26:948-955
70. Schwartzenberg-Bar-Yoseph F., Armoni M., Karnieli E.: The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res., 2004;64:2627-2633
71. Seatter M. J., De la Rue S. A., Porter L. M., Gould G. W.: QLS motif in transmembrane helix VII of the glucose transporter family interacts with the C-1 position of D-glucose and is involved in substrate selection at the exofacial binding site. Biochemistry, 1998;37:1322-1326
72. Semenza G. L.: Oxygen-dependent regulation of mitochondrial respiration by hypoxia-inducible factor 1. Biochem. J., 2007;405:1-9
73. Sergeant S. Kim H. D.: Inhibition of 3-O-methylglucose transport in human erythrocytes by forskolin. J. Biol. Chem., 1985;260:14677-14682
74. Shafee N., Kaluz S., Ru N., Stanbridge E. J.: PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines. Cancer Lett., 2009;282:109-115
75. Shahbazian D., Roux P. P., Mieulet V., Cohen M. S., Raught B., Taunton J., Hershey J. W., Blenis J., Pende M., Sonenberg N.: The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J., 2006;25:2781-2791
76. Shim H., Dolde C., Lewis B. C., Wu C. S., Dang G., Jungmann R. A., Dalla-Favera R., Dang C. V.: c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc. Natl. Acad. Sci. USA, 1997;94:6658-6663
77. Silva A., Gírio A., Cebola I., Santos C. I., Antunes F., Barata J. T.: Intracellular reactive oxygen species are essentials for PI3K/Akt/mTOR-dependent IL-7 mediated viability of T-cell acute lymphoblastic leukemia cells., Leukemia, 2011;25:960-967
78. Singh D., Banerji A. K., Dwarakanath B. S., Tripathi R. P., Gupta J. P., Mathew T. L., Ravindranath T., Jain V.: Optimizing cancer radiotherapy with 2-deoxy-D-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther. Oncol., 2005;181:507-514
79. Sparks C. A., Guertin D. A.: Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene, 2010;29:3733-3744
80. Steelman L. S., Chappell W. H., Abrams S. L., Kempf C. R., Long J., Laidler P., Mijatovic S., Maksimovic-Ivanic D., Stivala F., Mazzarino M. C., Donia M., Fagone P., Malaponte G., Nicoletti F., Libra M., Milella M., Tafuri A., Bonati A., Bäsecke J., Cocco L., Evangelisti C., Martelli A. M., Montalto G., Cervello M., McCubrey J. A.: Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging, 2011;3:192-222
81. Subbarayan P. R., Wang P. G., Lampidis T. J., Ardalan B., Braunschweiger P.: Differential expression of GLUT1 mRNA and protein levels correlates with increased sensitivity to the glyco-conjugated nitric oxide donor (2-glu-SNAP) in different tumor cell types. J. Chemother., 2008;20:106-111
82. Sui L., Dong Y., Watanabe Y., Yamaguchi F., Hatano N., Tsukamoto I., Izumori K., Tokuda M.: The inhibitory effect and possibile mechanisms of D-allose on cancer cell proliferation. Int. J. Oncol., 2005;27:907-912
83. Sun Y., Fang Y., Yoon M. S., Zhang C., Roccio M., Zwartkruis F. J., Armstrong M., Brown H. A., Chen J.: Phospholipase D1 is an effector of Rheb in the mTOR pathway. Proc. Natl. Acad. Sci. USA, 2008;105:8286-8291
84. Thangaraju M., Carswell K. N., Prasad P. D., Ganapathy V.: Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3. Biochem. J., 2009;417:379-389
85. st century. Am. J. Physiol. Endocrinol. Metab., 2010;298:E141-E145
86. Uhlenbrock K., Weiwad M., Wetzker R., Fischer G., Wittinghofer A., Rubio I.: Reassessment of the role of FKBP38 in the Rheb/mTORC1 pathway. FEBS Lett., 2009;583:965-970
87. Uldry M., Ibberson M., Hosokawa M., Thorens B.: GLUT2 is a high affinity glucosamine transporter. FEBS Lett., 2002;524:199-203
88. 18F-fluoro-2-deoxyglucose uptake on positron emission tomography In lung cancer. Gen. Thorac. Cardiovasc. Surg., 2010;58:405-410
89. Varshney R., Dwarakanath B. S., Jain V.: Radiosensitization by 6-aminonicotinamide and 2-deoxy-D-glucose in human cancer cells. Int. J. Radiat. Biol., 2005;81:397-408
90. Vera J. C., Reyes A. M., Cárcamo J. G., Velásquez F. V., Rivas C. I., Zhang R. H., Strobel P., Iribarren R., Scher H. I., Slebe J. C., Golde D. W.: Genistein is a natural inhibitor of hexose and dehydroascorbic acid transport through the glucose transporter, GLUT1. J. Biol. Chem., 1996;271:8719-8724
91. Vera J. C., Rosen O. M.: Functional expression of mammalian glucose transporters in Xenopus leavis oocytes: evidence for cell-dependent insulin sensitivity. Mol. Cell. Biol., 1989;9:4187-4195
92. Wang L., Harris T. E., Lawrence J. C. Jr: Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation. J. Biol. Chem., 2008;283:15619-15627
93. Watanabe R., Wei L., Huang J.: mTOR signaling, function, novel inhibitors, and therapeutic targets. J. Nucl. Med., 2011;52:497-500
94. Wieman H. L., Horn S. R., Jacobs S. R., Altman B. J., Kornbluth S., Rathmell J. C.: An essential role for the Glut1 PDZ-binding motif in growth factor regulation of Glut1 degradation and trafficking. Biochem J., 2009;418:345-367
95. Wood I. S., Trayhurn P.: Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br. J. Nutr., 2003;89:3-9
96. Xie H., Valera V. A., Merino M. J., Amato A. M., Signoretti S., Linehan W. M., Sukhatme V. P., Seth P.: LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol. Cancer Ther., 2009;8:626-635
97. Yun J., Rago C., Cheong I., Pagliarini R., Angenendt P., Rajagopalan H., Schmidt K., Willson J. K., Markowitz S., Zhou S., Diaz L. A. Jr, Velculescu V. E., Lengauer C., Kinzler K. W., Vogelstein B., Papadopoulos N.: Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science, 2009;325:1555-1559
98. Zhao F. Q., Keating A. F.: Functional properties and genomics of glucose transporters. Curr. Genomics, 2007;8:113-128
99. Zhou H., Huang S.: mTOR signaling in cancer cell motility and tumor metastasis. Crit. Rev. Eukaryot. Gene Expr., 2010;20:1-16
100. Zottola R. J., Cloherty E. K., Coderre P. E., Hansen A., Hebert D. N., Carruthers A.: Glucose transporter function is controlled by transporter oligomeric structure. A single, intramolecular disulfide promotes GLUT1 tetramerization. Biochemistry, 1995;34:9734-9747